COVID-19 Clinical Trial
Official title:
The Effects of Supplementation With ElderCraft® Elderberry Extract: A Randomized, Triple-blind, Placebo Controlled Clinical Trial.
Verified date | October 2022 |
Source | Franklin Health Research |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to confirm and quantify the effects of ElderCraft® elderberry extract on immune health.
Status | Recruiting |
Enrollment | 420 |
Est. completion date | June 30, 2023 |
Est. primary completion date | March 28, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 65 Years |
Eligibility | Inclusion Criteria: - Provision of signed and dated informed consent form - Stated willingness and demonstrated ability to comply with all study procedures and availability for the duration of the study - Aged 20-65 - Lives in the United States within driving distance of the research center - In good general health as evidenced by medical history - BMI <31 - Ability to take oral supplements and willing to commit to taking 2 capsules a day for 3 months - For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional month after the end of the intervention period - Employed full time in an occupation with direct and prolonged exposure to the public (i.e. teacher, healthcare provider, etc) or regularly engaged in high exposure activities. - Agreement to adhere to Lifestyle Considerations throughout study duration Exclusion Criteria: - Current use of the following pharmaceuticals: immunosuppressants - Pregnancy, trying to conceive or breastfeeding - Organ transplant recipient - Known allergic reactions to elderberries - Positive COVID-19 test within 180 days of the study period - COVID vaccine of any type scheduled during the intervention period or the week prior to the start of the study - Receipt of 4+ COVID-19 vaccines - Current diagnosis or lifetime history of an autoimmune condition (including but not limited to Lupus, Addisons, Graves, Hypothyroidism, Multiple Sclerosis, or Type 1 Diabetes) OR cancer OR chronic kidney disease OR chronic liver disease OR chronic lung disease (i.e. COPD, pulmonary embolism) OR cystic fibrosis OR severe heart disease (i.e. heart failure, coronary artery disease, cardiomyopathy) OR HIV infection OR immunocompromised status OR sickle cell disease OR tuberculosis - Recent dramatic weight changes (10% change in body weight in the last 6 months) - Existing usage of a polyphenol-based supplement, including but not limited to elderberry, cranberry, bilberry, quercetin, or resveratrol. - Existing usage of an immune supporting supplement such as echinacea, probiotics, elderberry, or any other dietary supplements marketed as immune support. - Routine dietary consumption of high levels of polyphenols or anthocyanins as determined by dietary intake questionnaire. |
Country | Name | City | State |
---|---|---|---|
United States | Franklin Health Research Center | Franklin | Tennessee |
Lead Sponsor | Collaborator |
---|---|
Franklin Health Research | Artemis International, IPRONA |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Digestive Health | The Franklin Digestive Health Scale measures gastrointestinal health across 4 domains, with higher scores indicating greater gastrointestinal health. | baseline and 13 weeks | |
Other | Adverse Events | Total number of adverse events during the 13 week intervention | 13 weeks | |
Primary | Incidence of Upper Respiratory Symptomatic Days | Total number of days with upper respiratory symptoms during the 90 day intervention. Symptoms are measured using the Franklin Immune Scale, which measures the severity of 50 symptoms. Scores range from 0 (symptom not present) to 5 (symptom is severe), with higher scores indicating greater severity. | 13 weeks | |
Primary | Incidence of Upper Respiratory Events | Total number of upper respiratory events during the 90 day intervention. An event is classified as a series of continuous days with upper respiratory symptoms. | 13 weeks | |
Primary | Duration of Upper Respiratory Events | Total number of days per upper respiratory event. An event is classified as a series of continuous days with upper respiratory symptoms. | 13 weeks | |
Primary | Symptom Severity | Average daily symptom score on the Franklin Immune Scale which measures the severity of 50 symptoms. Scores range from 0 (symptom not present) to 5 (symptom is severe), with higher scores indicating greater severity. | 13 weeks | |
Secondary | Incidence of COVID-19 | Total number of COVID-19 diagnoses during the 90 day period, as confirmed through an at-home laboratory verified diagnostic test. | 13 weeks | |
Secondary | Duration of COVID-19 | Total number of days per COVID-19 infection. An event is classified as a series of continuous days with COVID-19 symptoms and the receipt of a positive COVID-19 test. | 13 weeks | |
Secondary | Severity of COVID-19 | Average daily symptom score on the Franklin Immune Scale which measures the severity of 50 symptoms. Scores range from 0 (symptom not present) to 5 (symptom is severe), with higher scores indicating greater severity. | 13 weeks | |
Secondary | Incidence of influenza | Total number of influenza diagnoses during the 90 day period, as confirmed through an in-office diagnostic test. | 13 weeks | |
Secondary | Duration of influenza | Total number of days per influenza infection. An event is classified as a series of continuous days with flu-like symptoms and the receipt of a positive influenza test. | 13 weeks | |
Secondary | Severity of influenza | Average daily symptom score on the Franklin Immune Scale which measures the severity of 50 symptoms. Scores range from 0 (symptom not present) to 5 (symptom is severe), with higher scores indicating greater severity. | 13 weeks | |
Secondary | Energy Levels | The Franklin Energy Scale measures energy levels across 7 domains, with higher scores indicating greater energy levels. This produces a total energy score, as well as 7 subscores. | baseline and 13 weeks | |
Secondary | Sleep Quality | The Franklin Sleep Scale measures energy levels across 10 domains, with higher scores indicating greater sleep quality. | baseline and 13 weeks | |
Secondary | Cognitive Wellbeing | The Franklin Cognitive Health Scale measures brain health across 7 domains, with higher scores indicating greater cognitive well-being. | baseline and 13 weeks | |
Secondary | Stress Levels | The Franklin Stress Scale measures stress levels across 7 domains, with higher scores indicating greater stress management. | baseline and 13 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|